Saturday, July 11, 2026
🇺🇸 FDA

Drug profile · INN

hema-

hema- is an FDA-listed pharmaceutical active ingredient.

NMPA: clinical trials
Patents linked 20
Pipeline programs 211
News articles 0
Drug details — hema-
Class
—
Route
—
Patents
20
Programs
211
Data quality
0.70
← All drugs Related patents Pipeline programs Drug news hub Event calendar

Quick answer

hema- is an FDA-listed pharmaceutical active ingredient.

Key facts

INN hema-

Approval history

Regional status spokes: APAC status

Authority Status Date
NMPA clinical trials —

Pipeline programs

Browse pipeline
  1. 230LE301 Phase 3 · Biogen · Subacute Cutaneous Lupus Erythematosus, Chronic Cutaneous Lu
  2. 230LE303 Phase 3 · Biogen · systemic lupus erythematosus
  3. 230LE304 Phase 3 · Biogen · systemic lupus erythematosus
  4. 230LE306 Phase 3 · Biogen · Systemic lupus erythematosus
  5. 80202135SLE3001 Phase 3 · Janssen-Cilag International N.V · Systemic Lupus Erythematosus
  6. ALXN1210-TMA-313 Phase 3 · Alexion Europe SAS · Hematopoietic stem cell transplant-associated thrombotic mic
  7. APHP200073 Phase 3 · PARItec · Erythema multiforme (EM) in its severe form managed at the h
  8. APHP240920 Phase 3 · PARItec · Cutaneous lupus erythematosus

Related patents

Browse patents

  1. US 12281327

    Lymphohematopoietic engineering using CAS9 base editors

    Expires Mon Apr 17 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  2. US 12059437

    Methods and compositions for hematopoietic stem cell mobilization

    Expires Mon Aug 08 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  3. US 11944627

    Methods for treating hematological malignancies and Ewing's sarcoma

    Expires Mon Mar 28 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  4. US 11642379

    Hematopoietic stem cell engraftment

    Expires Mon May 04 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  5. US 11559565

    Methods for treating inflammatory disorders and traumatic brain injury using stabilized non-hematopoietic EPO short peptides

    Expires Mon Jan 19 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  6. US 11419875

    Compounds and compositions for treating hematological disorders

    Expires Mon Aug 18 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  7. US 11312953

    Compositions and methods of nucleic acid-targeting nucleic acids

    Expires Mon Apr 21 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  8. US 11110092

    Methods of treating hematologic cancers

    Expires Mon Sep 02 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  9. US 11052066

    Ultrapure tetrahydrocannabinol-11-oic acids

    Expires Mon Jul 01 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  10. US 10822299

    Compounds and methods for hematopoietic regeneration

    Expires Mon Oct 29 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  11. US 10369131

    Ultrapure tetrahydrocannabinol-11-oic acids

    Expires Mon Aug 01 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  12. US 10154986

    Ultrapure tetrahydrocannabinol-11-oic acids

    Expires Mon Dec 13 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  13. US 10137190

    Nucleic acid molecules encoding ferritin-hemagglutinin fusion proteins

    Expires Mon Nov 22 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  14. US 10125361

    Compositions and methods of nucleic acid-targeting nucleic acids

    Expires Mon Nov 08 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  15. US 10085964

    Ultrapure tetrahydrocannabinol-11-oic acids

    Expires Mon Sep 27 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  16. US 9909122

    Compositions and methods of nucleic acid-targeting nucleic acids

    Expires Mon Mar 01 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  17. US 9820964

    Ultrapure tetrahydrocannabinol-11-oic acids

    Expires Mon Nov 16 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  18. US 9809814

    Compositions and methods of nucleic acid-targeting nucleic acids

    Expires Mon Nov 02 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  19. US 9803194

    Compositions and methods of nucleic acid-targeting nucleic acids

    Expires Mon Oct 26 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  20. US 9801849

    Ultrapure tetrahydrocannabinol-11-oic acids

    Expires Mon Oct 26 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

Frequently asked questions

What is hema-?

hema- is an FDA-listed pharmaceutical active ingredient.

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.